Please login to the form below

Not currently logged in
Email:
Password:

    Pharmaceutical Market Europe (PME)

    PME is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts. The magazine provides insights and offers solutions to the issues that keep industry leaders awake at night.

    From the latest developments in cancer treatments and the strategies behind them to new marketing and commercialisation models and the regulations that underpin the fabric of the sector – PME's got it covered.

    PME is a trusted source for decision makers and influencers in pharma and healthcare who, through the practical and accessible content, have the knowledge to tackle whatever comes their way.

From: Research

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

ARV-471 is currently in a phase 2 trial for the treatment of patients ER-positive, HER2-negative locally advanced or metastatic breast cancer

From: Regulatory

Roche engaged in talks with FDA for Alzheimer’s drug candidate

Alzweb1CEO Severin Schwan told reporters Roche will complete a phase 3 trial of gantenerumab in the second half of 2022

From: Research

One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants

AZ NEWNew real-world data from Canada shows vaccine efficacy was lower against milder symptomatic disease with one dose

From: Regulatory

J&J, distributors reach $26bn settlement to address the opioid crisis in the US

J&J cottonwood driveThe proposed agreement would resolve claims of both states and local governments in the US

Articles

Pharmaceutical Market Europe - July/August 2021

Omnichannel communications, The importance of the patient voice in clinical trials, Hybrid working – making the new normal work for everyone

Pharmaceutical Market Europe (PME) magazine is also available on the iPhone/iPad as a free app

Editor - Iona Everson

Have your say...

Mark Caulfield departs from Genomics England to take on CEO role at Barts Life Sciences

Caulfield served as chief scientist at Genomics England, working on the 100,000 Genomes Project

Caulfield

'Nothing about us without us'

Why patient engagement is essential throughout the entire product life cycle

Meike Wenzel

Ashfield launches ‘end-to-end’ cell and gene therapy commercialisation network

The network, called EmerGENE, combines experts from Ashfield Health, Ashfield Engage and Ashfield Advisory

EmerGene

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....